Innoviva Net Income 2012-2026 | INVA
Innoviva net income from 2012 to 2026. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
|
Innoviva Annual Net Income (Millions of US $) |
|
|---|---|
| 2025 | $271 |
| 2024 | $23 |
| 2023 | $180 |
| 2022 | $214 |
| 2021 | $266 |
| 2020 | $224 |
| 2019 | $157 |
| 2018 | $395 |
| 2017 | $134 |
| 2016 | $60 |
| 2015 | $-19 |
| 2014 | $-168 |
| 2013 | $-171 |
| 2012 | $-19 |
| 2011 | $-115 |
|
Innoviva Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2026-06-30 | $-83 |
| 2026-03-31 | $187 |
| 2025-12-31 | $164 |
| 2025-09-30 | $90 |
| 2025-06-30 | $64 |
| 2025-03-31 | $-47 |
| 2024-12-31 | $20 |
| 2024-09-30 | $1 |
| 2024-06-30 | $-35 |
| 2024-03-31 | $37 |
| 2023-12-31 | $62 |
| 2023-09-30 | $82 |
| 2023-06-30 | $1 |
| 2023-03-31 | $35 |
| 2022-12-31 | $-68 |
| 2022-09-30 | $266 |
| 2022-06-30 | $1 |
| 2022-03-31 | $16 |
| 2021-12-31 | $10 |
| 2021-09-30 | $72 |
| 2021-06-30 | $89 |
| 2021-03-31 | $94 |
| 2020-12-31 | $54 |
| 2020-09-30 | $28 |
| 2020-06-30 | $77 |
| 2020-03-31 | $65 |
| 2019-12-31 | $46 |
| 2019-09-30 | $40 |
| 2019-06-30 | $38 |
| 2019-03-31 | $34 |
| 2018-12-31 | $264 |
| 2018-09-30 | $47 |
| 2018-06-30 | $55 |
| 2018-03-31 | $30 |
| 2017-12-31 | $58 |
| 2017-09-30 | $24 |
| 2017-06-30 | $35 |
| 2017-03-31 | $17 |
| 2016-12-31 | $25 |
| 2016-09-30 | $15 |
| 2016-06-30 | $15 |
| 2016-03-31 | $4 |
| 2015-12-31 | $4 |
| 2015-09-30 | $-5 |
| 2015-06-30 | $-8 |
| 2015-03-31 | $-11 |
| 2014-12-31 | $-16 |
| 2014-09-30 | $-21 |
| 2014-06-30 | $-64 |
| 2014-03-31 | $-68 |
| 2013-12-31 | $-50 |
| 2013-09-30 | $-47 |
| 2013-06-30 | $-36 |
| 2013-03-31 | $-37 |
| 2012-12-31 | $-31 |
| 2012-09-30 | $-35 |
| 2012-06-30 | $-37 |
| 2012-03-31 | $85 |
| 2011-12-31 | $-37 |
| 2011-09-30 | $-31 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.541B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1081.958B | 36.50 |
| Johnson & Johnson (JNJ) | United States | $663.276B | 25.34 |
| AbbVie (ABBV) | United States | $453.112B | 23.59 |
| Merck (MRK) | United States | $370.890B | 46.83 |
| Roche Holding AG (RHHBY) | Switzerland | $350.157B | 0.00 |
| Novartis AG (NVS) | Switzerland | $305.285B | 18.43 |
| Novo Nordisk (NVO) | Denmark | $208.069B | 11.59 |
| Pfizer (PFE) | United States | $162.156B | 9.33 |
| Sanofi (SNY) | France | $107.257B | 9.03 |
| Bayer (BAYRY) | Germany | $55.767B | 9.92 |